Cocaine dependence is a devastating disorder that is associated with a host of medical and psychosocial risks. This complex disorder is made up of distinct clinical components that are interwoven into a cycle of addiction (Figure 1). Cocaine activates ancient pleasure centers that dominate our thoughts, behaviors, and priorities, producing a pleasure-reinforced compulsion to use the drug. Repeated use dysregulates brain pleasure centers and paves the way to addiction through craving and impaired hedonic function.1 Euphoria and craving drive the cycle of addiction through positive and negative reinforcement, respectively, and they provide targets for pharmacological interventions.
Cocaine may also dysregulate neurons in the prefrontal cortex (PFC), which is the part of the brain that weighs the motivation to use cocaine. PFC dysfunction, in turn, may contribute to loss of control and denial. Human and animal research has identified neuronal mechanisms that underlie many of the clinical aspects of cocaine dependence, support a disease concept,and provide guidance for urgently needed pharmacological treatments.2
Cocaine produces pleasure that far exceeds the normal range of human experience and becomes inexorably crystallized in memory. The lure of cocaine euphoria should never be underestimated in clinical practice; its sheer power is illustrated by the fact that laboratory animals with unrestricted access to cocaine will self-administer until death. Cocaine produces a brief rush of pleasure and a constellation of stimulant effects (Table)3 that notably includes sexual arousal. Indeed, several lines of evidence indicate that cocaine activates sex reward circuits in the brain.3 Within minutes, cocaine pleasure gives way to intense craving that drives characteristic cocaine binges. As cocaine addiction progresses, individuals become increasingly willing to risk family turmoil, job loss, incarceration, medical problems, and even death in pursuit of the drug.
Symptoms of cocaine
intoxication and withdrawal*
|Psychomotor activation||Psychomotor retardation|
|Sexual arousal||Reduced libido (sexual dysfunction)|
|Racing thoughts||Sluggish thoughts|
|*Symptoms of cocaine intoxication and withdrawal are opposite, reflecting the activation and dysregulation of brain pleasure centers.3|
Cocaine euphoria has traditionally been ascribed to increased dopamine neurotransmission in the nucleus accumbens (NAc), a "universal addiction site" where addictive drugs and natural rewards (eg, sexual behaviors) have long been known to increase dopamine levels.1 Dopamine is released into the NAc by axons from the ventral tegmentum area (VTA), a reward-related midbrain region that also innervates the PFC, amygdala, and other limbic sites. Target neurons in the NAc have long axons that project to distant regions and release endogenous opioids (enkephalin or dynorphin) and γ-aminobutyric acid (GABA). These neurons have massive dendritic trees that can accommodate projections from as many as 400,000 neurons located in the PFC and other conscious structures,4 enabling the NAc to funnel, process, and transmit cortical information throughout reward-related circuits.
Cocaine increases synaptic dopamine levels in the NAc by blocking the dopamine transporter (DAT), a reuptake site that normally serves to clear dopamine from the synapse. Positron emission tomography (PET) demonstrates a close correlation between cocaine euphoria and the rate by which cocaine effectively binds the DAT.5 This explains why rapid routes of administration (eg, smoking, injecting) are associated with intense euphoria. PET studies using [11C] raclopride, a radioligand that competes with dopamine at D2 receptors, further demonstrate that stimulant euphoria is closely correlated with dopamine neurotransmission.5
Although this and other evidence for dopamine involvement in cocaine euphoria is compelling, glutamate is also important. Mice bred to lack the glutamatergic mGluR5 receptor will not self-administer cocaine, despite elevated dopamine levels in the NAc.6 Furthermore, it has recently been demonstrated that dopamine VTA neurons also release glutamate7 and form glutamatergic synaptic connections in the NAc.8 These and other findings suggest that cocaine euphoria requires concurrent glutamate and dopamine neurotransmission.9
1. Dackis CA, O'Brien CP. Cocaine dependence: a disease of the brain's reward centers. J Subst Abuse Treat. 2001; 21:111-117.
2. Vocci FJ, Elkashef A. Pharmacotherapy and other treatments for cocaine abuse and dependence. Curr Opin Psychiatry. 2005;18:265-270.
3. Dackis CA. Recent advances in the pharmacotherapy of cocaine dependence. Curr Psychiatry Rep. 2004;6: 323-331.
4. Kincaid AE, Zheng T, Wilson CJ. Connectivity and convergence of single corticostriatal axons. J Neurosci. 1998;18:4722-4731.
5. Volkow ND, Fowler JS, Wang GJ. The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropharmacology. 2004;47: 3-13.
6. Chiamulera C, Epping-Jordan MP, Zocchi A, et al. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci. 2001; 4:873-874.
7. Seutin V. Dopaminergic neurons: much more than dopamine? Br J Pharmacol. 2005;146:167-169.
8. Chuhma N, Zhang H, Masson J, et al. Dopamine neurons mediate a fast excitatory signal via their glutamatergic synapses. J Neurosci. 2004;24:972-981.
9. Dackis C, O'Brien C. Glutamatergic agents for cocaine dependence. Ann N Y Acad Sci. 2003;1003:328-345.
10. Dahl JP, Kampman KM, Oslin DW, et al. Association of a polymorphism in the Homer1 gene with cocaine dependence in an African American population. Psychiatr Genet. 2005;15:277-283.
11. Volkow ND, Wang GJ, Fowler JS, et al. Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am J Psychiatry. 1999;156:1440-1443.
12. Martinez D, Broft A, Foltin RW, et al. Cocaine dependence and d2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine- seeking behavior. Neuropsychopharmacology. 2004;29: 1190-1202.
13. Volkow ND, Chang L, Wang GJ, et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry. 2001;158:2015-2021.
14. Heinz A, Siessmeier T, Wrase J, et al. Correlation between dopamine D(2) receptors in the ventral striatum and central processing of alcohol cues and craving. Am J Psychiatry. 2004;161:1783-1789.
15. Czoty PW, Morgan D, Shannon EE, et al. Characterization of dopamine D1 and D2 receptor function in socially housed cynomolgus monkeys self-administer-ing cocaine. Psychopharmacology (Berl). 2004;174: 381-388.
16. Lile JA, Stoops WW, Allen TS, et al. Baclofen does not alter the reinforcing, subject-rated or cardiovascular effects of intranasal cocaine in humans. Psychopharmacology (Berl). 2004;171:441-449.
17. Sofuoglu M, Kosten TR. Novel approaches to the treatment of cocaine addiction. CNS Drugs. 2005;19: 13-25.
18. Dackis CA, Lynch KG, Yu E, et al. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend. 2003;70:29-37.
19. Myrick H, Malcolm R, Taylor B, LaRowe S. Modafinil: preclinical, clinical, and post-marketing surveillance—a review of abuse liability issues. Ann Clin Psychiatry. 2004;16:101-109.
20. Mignot E, Nishino S, Guilleminault C, Dement WC. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep. 1994;17:436-437.
21. Dackis CA, Kampman KM, Lynch KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology. 2005;30: 205-211.
22. Kampman KM, Alterman AI, Volpicelli JR, et al. Cocaine withdrawal symptoms and initial urine toxicology results predict treatment attrition in outpatient cocaine dependence treatment. Psychol Addict Behav. 2001;15: 52-59.
23. Nestler EJ. Historical review: Molecular and cellular mechanisms of opiate and cocaine addiction. Trends Pharmacol Sci. 2004;25:210-218.
24. Koob GF, Ahmed SH, Boutrel B, et al. Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci Biobehav Rev. 2004;27:739-749.
25. Robinson TE, Kolb B. Structural plasticity associated with exposure to drugs of abuse. Neuropharmacology. 2004;47:33-46.
26. Wu JC, Bell K, Najafi A, et al. Decreasing striatal 6-FDOPA uptake with increasing duration of cocaine withdrawal [see comments]. Neuropsychopharmacology. 1997;17:402-409.
27. Volkow ND, Wang GJ, Fowler JS, et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature. 1997;386:830-833.
28. Patkar AA, Hill KP, Sterling RC, et al. Serum prolactin and response to treatment among cocaine-dependent individuals. Addict Biol. Jan 2002;7:45-53.
29. Dackis CA, Gold MS. New concepts in cocaine addiction: the dopamine depletion hypothesis. Neurosci Biobehav Rev. 1985;9:469-477.
30. Mash DC, Staley JK. D3 dopamine and kappa opioid receptor alterations in human brain of cocaine-overdose victims. Ann N Y Acad Sci. 1999;877:507-522.
31. Little KY, Zhang L, Desmond T, et al. Striatal dopaminergic abnormalities in human cocaine users. Am J Psychiatry. 1999;156:238-245.
32. Todtenkopf MS, Marcus JF, Portoghese PS, Carlezon WA Jr. Effects of k-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology (Berl). 2004;172:463-470.
33. Keys AS, Mark GP, Emre N, Meshul CK. Reduced glutamate immunolabeling in the nucleus accumbens following extended withdrawal from self-administered cocaine. Synapse. 1998;30:393-401.
34. Xi ZX, Ramamoorthy S, Shen H, et al. GABA transmission in the nucleus accumbens is altered after withdrawal from repeated cocaine. J Neurosci. 2003;23: 3498-3505.
35. Mateo Y, Lack CM, Morgan D, et al. Reduced dopamine terminal function and insensitivity to cocaine following cocaine binge self-administration and deprivation. Neuropsychopharmacology. 2005;30:1455-1463.
36. Xi ZX, Ramamoorthy S, Baker DA, et al. Modulation of group II metabotropic glutamate receptor signaling by chronic cocaine. J Pharmacol Exp Ther. 2002;303: 608-615.
37. Dackis CA. New treatments for cocaine abuse. Drug Discov Today. 2005;2:79-86.
38. Carroll KM, Fenton LR, Ball SA, et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry. 2004;61:264-272.
39. Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of olanzapine for the treatment of cocaine dependence. Drug Alcohol Depend. 2003;70:265-273.
40. Jaffe JH, Cascella NG, Kumor KM, Sherer MA. Cocaine-induced cocaine craving. Psychopharmacology. 1989;97:59-64.
41. Kalivas PW, McFarland K, Bowers S, et al. Glutamate transmission and addiction to cocaine. Ann N Y Acad Sci. 2003;1003:169-175.
42. LaRowe SD, Mardikian P, Malcolm R, et al. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict. 2006;15:105-110.
43. Dackis C, O'Brien C. Neurobiology of addiction: treatment and public policy ramifications. Nat Neurosci. 2005; 8:1431-1436.
44. Garavan H, Pankiewicz J, Bloom A, et al. Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli. Am J Psychiatry. 2000;157: 1789-1798.
45. Kalivas PW, McFarland K. Brain circuitry and the reinstatement of cocaine-seeking behavior. Psychopharmacology (Berl). 2003;168:44-56.
46. Schultz W. Reward signaling by dopamine neurons. Neuroscientist. 2001;7:293-302.
47. Hotsenpiller G, Giorgetti M, Wolf ME. Alterations in behaviour and glutamate transmission following presentation of stimuli previously associated with cocaine exposure. Eur J Neurosci. 2001;14:1843-1855.
48. Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. 2004;75:233-240.
49. Brebner K, Childress AR, Roberts DC. A potential role for GABA(B) agonists in the treatment of psychostimulant addiction. Alcohol Alcohol. 2002;37:478-484.
50. Shoptaw S, Yang X, Rotheram-Fuller EJ, et al. Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry. 2003; 64:1440-1448.
51. Dackis CA, O'Brien CP. Clinical implications of cocaine-induced cortical depression (letter). Neuropsychopharmacology. 2005;3:1033.
52. Wang B, Shaham Y, Zitzman D, et al. Cocaine experience establishes control of midbrain glutamate and dopamine by corticotropin-releasing factor: a role in stress-induced relapse to drug seeking. J Neurosci. 2005;25: 5389-5396.
53. McFarland K, Davidge SB, Lapish CC, Kalivas PW. Limbic and motor circuitry underlying footshock-induced reinstatement of cocaine-seeking behavior. J Neurosci. 2004;24:1551-1560.
54. Kampman KM, Volpicelli JR, Mulvaney F, et al. Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug Alcohol Depend. 2001;63:69-78.
55. Franklin TR, Acton PD, Maldjian JA, et al. Decreased gray matter concentration in the insular, orbitofrontal, cingulate, and temporal cortices of cocaine patients. Biol Psychiatry. 2002;51:134-142.